The Company is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others. The Company was established on June 19, 2013. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on December 19, 2019.
Headquarters
92, Myeongdal-Ro, Seocho-Gu, Seoul
Seoul; Seoul;
Contact Details: Purchase the Medpacto, Inc. report to view the information.
Website: http://www.medpacto.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service